We are live on ! Find out more
PCVX icon

Vaxcyte
PCVX

223 hedge funds and large institutions have $6.51B invested in Vaxcyte in 2023 Q4 according to their latest regulatory filings, with 37 funds opening new positions, 86 increasing their positions, 69 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

236% more call options, than puts

Call options by funds: $9.9M | Put options by funds: $2.94M

131% more first-time investments, than exits

New positions opened: 37 | Existing positions closed: 16

26% more capital invested

Capital invested by funds: $5.17B → $6.51B (+$1.34B)

25% more repeat investments, than reductions

Existing positions increased: 86 | Existing positions reduced: 69

10% more funds holding

Funds holding: 202 → 223 (+21)

8% more funds holding in top 10

Funds holding in top 10: 13 → 14 (+1)

0.88% more ownership

Funds ownership: 108.03% → 108.91% (+0.88%)

Holders
223
Holders Change
+21
Holders Change %
+10.4%
% of All Funds
3.25%
Holding in Top 10
14
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+7.69%
% of All Funds
0.2%
New
37
Increased
86
Reduced
69
Closed
16
Calls
$9.9M
Puts
$2.94M
Net Calls
+$6.96M
Net Calls Change
+$6.35M

Top Buyers

1
BlackRock
BlackRock
New York
+$60M
2
Morgan Stanley
Morgan Stanley
New York
+$34.5M
3
DGM
Darwin Global Management
Jersey
+$30.1M
4
Westfield Capital Management
Westfield Capital Management
Massachusetts
+$23.5M
5
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
+$20M

Top Sellers

1
MVM
Medicxi Ventures Management
Jersey
-$53.5M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
-$32.3M
3
FAM
Fred Alger Management
New York
-$22M
4
NIP
Nicholas Investment Partners
California
-$18.1M
5
B
Braidwell
Connecticut
-$17.1M
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$893M +$7.08M +136,328 +1%
BlackRock
2
BlackRock
New York
$539M +$60M +1,154,596 +16%
Vanguard Group
3
Vanguard Group
Pennsylvania
$531M +$8.73M +168,125 +2%
RCM
4
RA Capital Management
Massachusetts
$496M – – –
Janus Henderson Group
5
Janus Henderson Group
United Kingdom
$438M -$4.11M -79,212 -1%
Wellington Management Group
6
Wellington Management Group
Massachusetts
$278M -$8.66M -166,792 -4%
Capital Research Global Investors
7
Capital Research Global Investors
California
$216M +$3.95M +75,980 +2%
State Street
8
State Street
Massachusetts
$213M +$12.7M +244,269 +8%
T. Rowe Price Associates
9
T. Rowe Price Associates
Maryland
$168M +$13.5M +260,170 +11%
Geode Capital Management
10
Geode Capital Management
Massachusetts
$124M +$5.11M +98,392 +5%
AllianceBernstein
11
AllianceBernstein
Tennessee
$120M -$1.49M -28,783 -1%
DCM
12
Driehaus Capital Management
Illinois
$105M +$18.2M +350,484 +26%
FAM
13
Fred Alger Management
New York
$105M -$22M -423,116 -20%
Jennison Associates
14
Jennison Associates
New York
$92.7M -$14.5M -278,537 -16%
Westfield Capital Management
15
Westfield Capital Management
Massachusetts
$91.4M +$23.5M +451,677 +45%
B
16
Braidwell
Connecticut
$81M -$17.1M -329,588 -20%
T. Rowe Price Investment Management
17
T. Rowe Price Investment Management
Maryland
$78.3M +$2.15M +41,413 +3%
FLSM
18
Frazier Life Sciences Management
California
$73.1M – – –
O
19
OrbiMed
New York
$72.4M +$7.58M +145,943 +14%
Pictet Asset Management
20
Pictet Asset Management
Switzerland
$72.2M -$16.9M -325,573 -22%
CC
21
Commodore Capital
New York
$69.1M – – –
PA
22
Perceptive Advisors
New York
$68.4M -$13.2M -254,265 -19%
Franklin Resources
23
Franklin Resources
California
$67.6M +$6.28M +120,985 +13%
Morgan Stanley
24
Morgan Stanley
New York
$67.5M +$34.5M +665,180 +162%
KCM
25
Kynam Capital Management
New Jersey
$63M -$15.6M -300,000 -23%
1
2 3 4 5

PCVX Hedge Fund Activity: Q4 2023 in Review

223 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Vaxcyte (PCVX) for Q4 2023, worth a combined $6.51B — up 26% from $5.17B a quarter earlier.

Buyers outnumbered sellers: 37 funds opened new PCVX positions and 16 closed out — a net gain of 21 holders — while 86 added to existing stakes and 69 trimmed.

The largest buyer was BlackRock, adding an estimated $60M. The largest seller was Medicxi Ventures Management, exiting entirely with an estimated $53.5M sold.

  • 223 institutional investors held Vaxcyte (PCVX) as of Q4 2023, up from 202 in Q3 2023.
  • Funds reported $6.51B of Vaxcyte stock for Q4 2023, up 26% quarter-over-quarter.
  • 37 funds opened new Vaxcyte positions in Q4 2023 and 16 closed out, a net change of +21 holders.
  • The largest Vaxcyte buyer in Q4 2023 was BlackRock, an estimated $60M added.
  • The largest Vaxcyte seller in Q4 2023 was Medicxi Ventures Management, an estimated $53.5M sold.

Based on aggregated 13F filings for Q4 2023.